This clinical trial is focused on studying the effects of a medication called deucravacitinib in adults with a condition known as Sjögren’s syndrome. Sjögren’s syndrome is an autoimmune disease, which means the body’s immune system mistakenly attacks its own cells, leading to symptoms like dry eyes and mouth. The study will use deucravacitinib in two different doses, 3 mg and 6 mg, in the form of film-coated tablets taken orally. Some participants will receive a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how effective and safe deucravacitinib is for treating active Sjögren’s syndrome. Participants will be randomly assigned to receive either the medication or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their health and any changes in their symptoms. The main goal is to see if there is an improvement in the disease activity after 52 weeks of treatment.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether deucravacitinib can be a beneficial treatment option for people with Sjögren’s syndrome. This research could potentially lead to new ways to manage the symptoms and improve the quality of life for those affected by this condition.